Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun 1;17(11):3742-50.
doi: 10.1158/1078-0432.CCR-10-3405. Epub 2011 Mar 8.

The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing

Paul D P Pharoah  1 , Rachel T Palmieri, Susan J Ramus, Simon A Gayther, Irene L Andrulis, Hoda Anton-Culver, Natalia Antonenkova, Antonis C Antoniou, David Goldgar; BCFR Investigators; Mary S Beattie, Matthias W Beckmann, Michael J Birrer, Natalia Bogdanova, Kelly L Bolton, Wendy Brewster, Angela Brooks-Wilson, Robert Brown, Ralf Butzow, Trinidad Caldes, Maria Adelaide Caligo, Ian Campbell, Jenny Chang-Claude, Y Ann Chen, Linda S Cook, Fergus J Couch, Daniel W Cramer, Julie M Cunningham, Evelyn Despierre, Jennifer A Doherty, Thilo Dörk, Matthias Dürst, Diana M Eccles, Arif B Ekici, Douglas Easton; EMBRACE Investigators; Peter A Fasching, Anna de Fazio, David A Fenstermacher, James M Flanagan, Brooke L Fridley, Eitan Friedman, Bo Gao, Olga Sinilnikova; GEMO Study Collaborators; Aleksandra Gentry-Maharaj, Andrew K Godwin, Ellen L Goode, Marc T Goodman, Jenny Gross, Thomas V O Hansen, Paul Harnett, Matti Rookus; HEBON Investigators; Tuomas Heikkinen, Rebecca Hein, Claus Høgdall, Estrid Høgdall, Edwin S Iversen, Anna Jakubowska, Sharon E Johnatty, Beth Y Karlan, Noah D Kauff, Stanley B Kaye, Georgia Chenevix-Trench; kConFab Investigators and the Consortium of Investigators of Modifiers of BRCA1/2; Linda E Kelemen, Lambertus A Kiemeney, Susanne Krüger Kjaer, Diether Lambrechts, James P Lapolla, Conxi Lázaro, Nhu D Le, Arto Leminen, Karin Leunen, Douglas A Levine, Yi Lu, Lene Lundvall, Stuart Macgregor, Tamara Marees, Leon F Massuger, John R McLaughlin, Usha Menon, Marco Montagna, Kirsten B Moysich, Steven A Narod, Katherine L Nathanson, Lotte Nedergaard, Roberta B Ness, Heli Nevanlinna, Stefan Nickels, Ana Osorio, Jim Paul, Celeste Leigh Pearce, Catherine M Phelan, Malcolm C Pike, Paolo Radice, Mary Anne Rossing, Joellen M Schildkraut, Thomas A Sellers, Christian F Singer, Honglin Song, Daniel O Stram, Rebecca Sutphen, Annika Lindblom; SWE-BRCA Investigators; Kathryn L Terry, Ya-Yu Tsai, Anne M van Altena, Ignace Vergote, Robert A Vierkant, Allison F Vitonis, Christine Walsh, Shan Wang-Gohrke, Barbara Wappenschmidt, Anna H Wu, Argyrios Ziogas, Andrew Berchuck, Harvey A Risch; Ovarian Cancer Association Consortium
Affiliations

The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing

Paul D P Pharoah et al. Clin Cancer Res. .

Abstract

Purpose: An assay for the single-nucleotide polymorphism (SNP), rs61764370, has recently been commercially marketed as a clinical test to aid ovarian cancer risk evaluation in women with family histories of the disease. rs67164370 is in a 3'-UTR miRNA binding site of the KRAS oncogene and is a candidate for epithelial ovarian cancer (EOC) susceptibility. However, only one published article, analyzing fewer than 1,000 subjects in total, has examined this association.

Experimental design: Risk association was evaluated in 8,669 cases of invasive EOC and 10,012 controls from 19 studies participating in the Ovarian Cancer Association Consortium, and in 683 cases and 2,044 controls carrying BRCA1 mutations from studies in the Consortium of Investigators of Modifiers of BRCA1/2. Prognosis association was also examined in a subset of five studies with progression-free survival (PFS) data and 18 studies with all-cause mortality data.

Results: No evidence of association was observed between genotype and risk of unselected EOC (OR = 1.02, 95% CI: 0.95-1.10), serous EOC (OR = 1.08, 95% CI: 0.98-1.18), familial EOC (OR = 1.09, 95% CI: 0.78-1.54), or among women carrying deleterious mutations in BRCA1 (OR = 1.09, 95% CI: 0.88-1.36). There was little evidence for association with survival time among unselected cases (HR = 1.10, 95% CI: 0.99-1.22), among serous cases (HR = 1.12, 95% CI = 0.99-1.28), or with PFS in 540 cases treated with carboplatin and paclitaxel (HR = 1.18, 95% CI: 0.93-1.52).

Conclusions: These data exclude the possibility of an association between rs61764370 and a clinically significant risk of ovarian cancer or of familial ovarian cancer. Use of this SNP for ovarian cancer clinical risk prediction, therefore, seems unwarranted.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Funnel plots of study-specific odds ratios for association between rs61764370 and ovarian cancer risk. (a) all cases; (b) serous cases; (c) cases with a family history of ovarian cancer in a first-degree relative.
See this image and copyright information in PMC

Comment in

References

    1. Gayther SA, Pharoah PD. The inherited genetics of ovarian and endometrial cancer. Curr Opin Genet Dev. 2010;20:231–8. - PMC - PubMed
    1. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet. 2009;41:996–1000. - PMC - PubMed
    1. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics. 2010;42:880–4. - PMC - PubMed
    1. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics. 2010;42:874–9. - PMC - PubMed
    1. Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Research. 2010;70:6509–15. - PMC - PubMed

Publication types

MeSH terms

Grants and funding